Literature DB >> 18209581

Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.

Kazunari Murakami1, Tadayoshi Okimoto, Masaaki Kodama, Ryugo Sato, Koichiro Watanabe, Toshio Fujioka.   

Abstract

GOALS: We compared the eradication results of retreatment of eradication with proton pump inhibitor (PPI) plus amoxicillin and metronidazole for patients with Helicobacter pylori infection not eradicated by initial treatment with PPI plus amoxicillin and clarithromycin.
BACKGROUND: In Japan, the guideline proposes that the use of metronidazole in a triple therapy containing PPI, PPI plus amoxicillin and metronidazole is desirable in retreatment. However, there are no reports comparing various retreatment using different PPIs.
METHODS: After initial treatment failure with a PPI plus amoxicillin and clarithromycin, 169 patients were randomized to a PPI (rabeprazole, lansoprazole, or omeprazole) plus amoxicillin and metronidazole given b.i.d. for 7 days.
RESULTS: Pretreatment susceptibility testing showed a high level of clarithromycin resistance (78%). The over all eradication rates were similar with the 3 PPIs, 91.1% range 90.1 to 91.4 with intention-to-treat analysis. The presence of metronidazole resistance reduced the eradication rate by approximately 40% (from 96.6% to 57.1%, P<0.05).
CONCLUSIONS: In Japan, the combination of a PPI plus amoxicillin and metronidazole provide excellent eradication rates after initial treatment failure with a PPI plus amoxicillin and clarithromycin. The results with metronidazole resistant strains are less satisfactory and pretreatment susceptibility testing may become needed if the prevalence of metronidazole resistant H. pylori increase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209581     DOI: 10.1097/MCG.0b013e31802cbc1a

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.

Authors:  Mario Del Tacca; Giuseppe Pasqualetti; Antonello Di Paolo; Agostino Virdis; Gabriele Massimetti; Giovanni Gori; Daniele Versari; Stefano Taddei; Corrado Blandizzi
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

Review 3.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

4.  Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective.

Authors:  Seiji Shiota; Kazunari Murakami; Toshio Fujioka; Yoshio Yamaoka
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-04       Impact factor: 3.869

5.  Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole.

Authors:  Hai-lun Zheng; Yong-mei Hu; Jun-jun Bao; Jian-ming Xu
Journal:  Acta Pharmacol Sin       Date:  2010-03-22       Impact factor: 6.150

6.  Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.

Authors:  Makoto Sasaki; Naotaka Ogasawara; Keiko Utsumi; Naohiko Kawamura; Tskeshi Kamiya; Hiromi Kataoka; Satoshi Tanida; Tsutomu Mizoshita; Kunio Kasugai; Takashi Joh
Journal:  J Clin Biochem Nutr       Date:  2010-06-17       Impact factor: 3.114

7.  Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.

Authors:  Qi Chen; Wei Zhang; Qingyan Fu; Xiao Liang; Wenzhong Liu; Shudong Xiao; Hong Lu
Journal:  Am J Gastroenterol       Date:  2016-09-27       Impact factor: 10.864

Review 8.  Helicobacter pylori infection in Japan.

Authors:  Seiji Shiota; Kazunari Murakawi; Rumiko Suzuki; Toshio Fujioka; Yoshio Yamaoka
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-01       Impact factor: 3.869

9.  Rescue Therapy for Helicobacter pylori Infection 2012.

Authors:  Javier P Gisbert
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

Review 10.  Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.

Authors:  Muhammad Miftahussurur; Yoshio Yamaoka
Journal:  Molecules       Date:  2015-04-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.